Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- DVYSR.ST
- Price
- 107.60
- Stock movement down
- -2.40 (-2.18%)
- Company name
- Devyser Diagnostics AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Diagnostics & Research
- Market cap
- 1.79B
- Ent value
- 1.83B
- Price/Sales
- 7.38
- Price/Book
- 5.26
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 61.89
- PEG
- -
- EPS growth
- -
- 1 year return
- -6.43%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2026-01-16
DIVIDENDS
DVYSR.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 118.67 |
| EV to EBITDA | 120.93 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.38 |
| Price to Book | 5.26 |
| EV to Sales | 7.52 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 16.65M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | 1.74 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 84.90M |
| Net receivables | 59.10M |
| Total current assets | 205.70M |
| Goodwill | 6.70M |
| Intangible assets | 141.00M |
| Property, plant and equipment | 0.00 |
| Total assets | 459.90M |
| Accounts payable | 10.60M |
| Short/Current long term debt | 51.50M |
| Total current liabilities | 74.00M |
| Total liabilities | 119.00M |
| Shareholder's equity | 340.90M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 109.60 |
| Daily high | 109.60 |
| Daily low | 106.00 |
| Daily Volume | 6K |
| All-time high | 157.80 |
| 1y analyst estimate | 153.83 |
| Beta | 0.75 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Feb 2026 |
Downside potential
Loading...
Downside potential data
| DVYSR.ST | S&P500 | |
| Current price drop from All-time high | -31.81% | -0.50% |
| Highest price drop | -37.86% | -19.00% |
| Date of highest drop | 11 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -14.95% | -2.50% |
| Avg time to new high | 32 days | 6 days |
| Max time to new high | 109 days | 89 days |
COMPANY DETAILS
Marketcap
1.79B
Marketcap category
Small-cap
Description
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is based in Årsta, Sweden.
Employees
108
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Devyser Diagnostics AB (FRA:OL0) reports a 20% sales growth and strong cash position, while navigating distributor sales decline and profitability hurdles.
November 13, 2025
Devyser Diagnostics (OM:DVYSR) remains unprofitable, with losses having grown 16.9% per year over the past five years. However, the company is forecast to become profitable within the next three years...
November 6, 2025
In September 2025, the European markets have been navigating a complex economic landscape, with the pan-European STOXX Europe 600 Index ending slightly lower amid a series of monetary policy decisions...
September 24, 2025
As the European market experiences a modest upswing, with the pan-European STOXX Europe 600 Index rising by 1.40% amid hopes for lower U.S. borrowing costs, investors are keenly observing growth oppor...
August 26, 2025
The European market has been experiencing a mixed performance with the pan-European STOXX Europe 600 Index ending roughly flat, as investors remain cautious amid ongoing U.S. and European trade discus...
July 25, 2025
As European markets navigate a landscape of mixed stock index performances and ongoing trade discussions, investors are keenly observing growth opportunities within the region. In this context, compan...
July 25, 2025
Devyser Diagnostics AB (FRA:OL0) reports a 27% revenue increase and unveils new products amid regional market expansion and cash flow challenges.
July 23, 2025